OTLK - OUTLOOK THERAPEUTICS INC logo

OTLK

OUTLOOK THERAPEUTICS INC

Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies for ophthalmic conditions. Its main product, ONS-5010, targets wet age-related macular degeneration and is currently in Phase III clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$2today

Score Overview

1 Year
Score
Net Growth-64.77%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-85.46%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-93.48%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-92.98%
Net Trend40%
Net Income Consistency
Rev Growth-93.10%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-92.98%
Net Trend40%
Net Income Consistency
Rev Growth-93.10%
Rev Trend40%
Revenue Consistency

See the full market ranking โ†’

OUTLOOK THERAPEUTICS INC fundamental performance

Across OUTLOOK THERAPEUTICS INC's full reported history, from 2016 to 2025, revenue declined from $ 2M to $ 1M and net income went from -$ 53M to -$ 62M. Revenue increased in 40% of the years measured; net income in 40%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.10โ€”
1 Year2025-08-12
$ 2.09-47.37%
5 Years2021-08-12
$ 50.60-97.83%
10 Years2016-08-12
$ 582.40-99.81%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 205.53K-$ 102M$ 8M
2025$ 1M-$ 62M$ 8M
2024$ 170.12K-$ 75M$ 14M
2023$ 0.00-$ 58M$ 23M
2022$ 0.00-$ 66M$ 17M
2021$ 0.00-$ 53M$ 14M
2020$ 5M-$ 35M$ 12M
2019$ 8M-$ 34M$ 8M
2018$ 3M-$ 30M$ 1M
2017$ 3M-$ 38M$ 3M
IPO2016$ 2M-$ 53M$ 2M

Explore beyond OTLK

You're looking at OUTLOOK THERAPEUTICS INC. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies